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Proteins necessary for the normal regulation of the cell cycle include minichromosome maintenance protein 2 (Mcm2) and geminin.
These are overexpressed in several premalignant and malignant tumours. The Mcm2/Ki67 ratio can be used to estimate the
population of cells that are in early G1 (licensed to proliferate), and the geminin/Ki67 ratio can determine the relative length of G1.
A high ratio indicates a short G1 and a high rate of cell proliferation. Mcm2 and geminin have been scarcely explored in oral epithelial
dysplasia (OED) and oral squamous-cell carcinoma (OSCC). The purpose of this study was to identify the expression pattern of
Mcm2, Ki67 and geminin in normal oral mucosa (NOM), OED and their subsequent OSCC, to determine if expression could help
predict the prognosis of OED. Paraffin sections of 41 OED cases that progressed to carcinoma, 40 OED without malignant
progression, 38 OSCC and 15 NOM were immunostained with antibodies against Mcm2, geminin and Ki67. Labelling indices (LIs)
increased progressively from NOM, OED and OSCC (Mcm2, Po0.001; geminin, Po0.001 and Ki67, Po0.001). In all the OED cases
(n¼81) the levels of expression of Mcm2 (LI, 73.6), geminin (LI, 24.4) and Ki67 (LI, 44.5) were elevated indicating a constant cell-
cycle re-entry. When the OED groups were compared, Mcm2 protein expression was higher in the OED with malignant progression
(P¼0.04), likewise there was a significant increase in the Mcm2/Ki67 and geminin/Ki67 ratios (P¼0.04 and 0.02 respectively). Mcm2
and geminin proteins seem to be novel biomarkers of growth and may be useful prognostic tools for OED.
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Oral squamous-cell carcinoma (OSCC) represents the majority of
malignant lesions of the oral cavity. Despite refinement of surgical
techniques in the past few decades once invasive cancer is formed,
the prognosis is poor with an average 5-year survival rate of 40% of
affected patients (Mork, 1998; Diaz et al, 2003). Early diagnosis of
OSCC can improve patient survival and reduce significantly the
high mortality rates. It is thought that most, if not all, OSCC are
preceded by a period during which the affected epithelium shows
evidence of epithelial dysplasia, although this may not always be
clinically apparent (Napier and Speight, 2008). Currently, there are
no markers that can reliably predict malignant progression in oral
dysplastic lesions.
Cell-cycle regulatory proteins, including those that promote
initiation of DNA synthesis, such as minichromosome
maintenance proteins (MCM) and those that help to regulate cell
differentiation and cell proliferation such as geminin are
deregulated in a number of malignant lesions from different
human organs. These have been shown to be effective markers for
the early detection of cancer, particularly in samples from
suspected epithelial malignancies (Freeman et al, 1999; Stoeber
et al, 1999; Gonzalez et al, 2004).
Minichromosome maintenance proteins (Mcm 2–7) are a pre-
requisite for DNA replication and cell-cycle initiation (Kearsey and
Labib, 1998) and are expressed throughout the whole cell cycle
including cells leaving G0 to enter into the early G1 phase. This
characteristic is not found in Ki67, which is widely used to assess
proliferation; and therefore MCM proteins specifically Mcm5 and
Mcm2 have been proposed as potential prognostic markers in
dysplastic lesions and cancer (Freeman et al, 1999; Stoeber et al,
1999; Alison et al, 2002; Going et al, 2002).
Geminin, a novel proliferation marker is present from the G1–S
transition to early M phases (McGarry and Kirschner, 1998) and
helps to regulate cell-cycle initiation by impeding a second pre-
replication complex assembly once replication has started
(McGarry and Kirschner, 1998; Tachibana et al, 2005). It has also
been suggested that geminin levels may be altered in cancer cells as
it has been found to be overexpressed in several cancer cell lines
(Xouri et al, 2004). In addition, elevated expression has been
linked with a poor clinical outcome in renal cell carcinomas
(Dudderidge et al, 2005), and has been shown in a range of other
malignancies (Wohlschlegel et al, 2002; Shetty et al, 2005).
Ki67 is present throughout the complete cell cycle with the
exception of early G1 phase (Gerdes et al, 1984). When Mcm2 and
geminin are evaluated along with Ki67, the combination may
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sprovide extra information about proliferation rates in epithelial
compartments (Quaglia et al, 2006). The geminin/Ki67 ratio can
potentially evaluate the relative length of G1. The higher the ratio,
the shorter G1 indicating an increased proliferation rate and
therefore a poor prognosis, as shown in oligodendroglial tumours
(Wharton et al, 2004). Another suggested prognostic parameter is
the Mcm2/Ki67 ratio (Shetty et al, 2005), which can estimate the
proportion of cells that are licensed to proliferate (early G1).
The purpose of this study was to determine the immuno-
histochemical expression pattern of these proteins in normal oral
mucosa (NOM), oral epithelial dysplasia (OED) and OSCC, and to
determine if abnormal expression could serve as a prognostic
marker of malignant progression in OED.
MATERIAL AND METHODS
The study design was a retrospective case–control study identify-
ing lesions of OED that had progressed to malignancy and
comparing the protein expression with a cohort of closely matched
lesions that had not progressed at the time of sampling. Ethical
approval was obtained from the South Sheffield Research Ethics
Committee (SSREC/03/206).
Patient selection
From a total of over 1000 cases of OED in the archives of the
diagnostic service of the Oral and Maxillofacial Pathology
Department of the University of Sheffield, 41 were identified that
had progressed to OSCC. For each case the first biopsy showing
evidence of dysplasia was chosen for analysis. From the remaining
cases 40 closely matched OED that had not progressed to
carcinoma after a minimum follow-up of 4.5 years were selected.
Of the 41 cases that had progressed, 38 of the OSCC were available
for analysis.
The final total of 134 cases selected for analysis comprised 41
OED that had progressed to carcinoma, 40 OED that did not show
malignant progression, 38 OSCC from the 41 cases that had
progressed and 15 samples of NOM. If multiple biopsies for OED
were present from the same patient, the first OED biopsy was
selected; if the first biopsy was from a different site to that of the
subsequent OSCC, then, if available, the next biopsy that matched
the same site as the subsequent OSCC was chosen. Synchronous
lesions were excluded by only selecting cases where the minimum
time between the diagnosis of OED and carcinoma was 6 months.
OED and OSCC were histopathologically graded by two experi-
enced oral pathologists (PMS and GTC) according to the latest
WHO guidelines (Barnes et al, 2005).
Immunohistochemistry
The antibodies used in this study were anti-Mcm2 (BM28) mouse
anti-human monoclonal antibody (clone 46; BD Transduction
Laboratories, Lexington, KY, USA), geminin 95 (Gem95) poly-
clonal rabbit anti-human (Wharton et al, 2004) antibody and anti-
human Ki67 monoclonal mouse antibody (clone MIB-1) (Dako,
Glostrup, Denmark). All these proteins have been previously
characterised (Gerdes et al, 1984; Todorov et al, 1994; Lea et al,
2003; Wharton et al, 2004).
Paraffin-embedded formalin-fixed tissue sections (4mm) were
de-waxed in xylene and re-hydrated through graded alcohols to
water. For antigen retrieval, sections were pre-treated in a pressure
cooker, in 0.1 M citrate buffer (pH 6.0) for 1.5min for Ki67, and
3min for Mcm2 and Gem95. Endogenous peroxidase activity was
inhibited using peroxidase-blocking solution (DakoCytomation,
Glostrup, Denmark) for 10min. Tris buffer saline (TBS) sections
were incubated with primary antibody for 1h at room temperature
using the following dilutions: Mcm2 (1:1000), Ki67 (1:50) and
Gem95 (1:800). The detection system was ChemMate Detection kit
(DakoCytomation), which included application of biotinylated
secondary antibody for 30min and horseradish peroxidase for
30min. Two washes with TBS were applied between the primary
and secondary antibodies. Positive expression was visualised after
7min incubation with DAB. Slides were washed in running tap
water, counterstained with Mayer’s haematoxylin and mounted
with low-viscosity DPX mounting medium.
Quantification method
Five representative fields per slide were examined at  400
magnification under a light microscope with a rotating stage.
Representative fields in OED were selected according to the most
dysplastic areas and in OSCC were selected from the invasive front
of the tumour. An eyepiece graticule was used and the epithelial–
connective tissue interface was taken as the base of the square. All
epithelial cells inside the area of the graticule were counted.
Positive and negative epithelial cells and the total number of cells
were recorded using a manual cell counter (The Denominator Co.,
CT, USA) and recorded in a computer. The labelling index (LI) was
calculated by dividing the number of positive cells by the total
number of cells per case and multiplying by 100. Intra-observer
error was tested by re-examining 10% of the total number of cases.
There were high levels of agreement according to the inter-class
correlation coefficient for continuous data (P¼0.00).
Statistical analysis
Statistical analyses were carried out using the SPSS 14.0 and
GraphPad InStat statistical software. Mcm2, Ki67 and geminin
were normally distributed according to the Kolmogorov–Smirnov
test. Although Mcm2/Ki67 and geminin/Ki67 ratios were normally
distributed, because of their intrinsic constrained range of results
these were treated as non-parametric. Therefore ANOVA and t-test
analysis were used to evaluate differences between Mcm2, Ki67 and
geminin LIs in the NOM, OED and OSCC groups. Mann–Whitney
and Kruskal–Wallis tests were used to evaluate differences in the
Mcm2/KI67 and geminin/Ki67 ratios. The general linear model
(GLM) of repeated-measures analyses was used to evaluate the
differences among the LI of the proteins (Mcm2, Ki67 and
geminin) in every group (e.g. NOM or OED or OSCC). Scatter
plots were used to observe the associations between proteins.
Spearman’s correlation coefficient was used to evaluate correlation
between protein expression and grade of dysplasia.
RESULTS
In the group of OED that progressed to carcinoma the mean age of
the patients was 59.9 (standard deviation (s.d.) ±15.6) with 23
men (56%) and 18 women (44%). Malignant transformation
occurred within 6–200 months (mean 56.6±52.6). Twenty-nine
lesions were graded as severe epithelial dysplasia, eleven as
moderate and one as mild. In the group of OED with no history of
malignant progression the mean age was 60.3 (±14.8) and there
was a follow-up time of 54–349 months (mean 176.0±64); 25
(62.5%) were men and 15 (37.5%) were women. Twenty-three
lesions were graded as severe epithelial dysplasia and 17 as
moderate. Of the total 81 OED samples 1 was mild dysplasia, 28
were moderate dysplasias and 52 were severe dysplasias. The mean
age of the OSCC group was 65.4 (±15.9). Five cases were early
invasive OSCC, 22 were well differentiated, 10 were moderately
differentiated and 1 was poorly differentiated. The mean age of the
NOM cases was 37.2 (±19.1).
From the 134 cases, high-quality immunohistochemical staining
was available in 131 samples for Mcm2, 129 samples for Ki67 and
133 samples for geminin.
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Normal oral mucosa showed the lowest LI for Mcm2, Ki67 and
geminin and a low geminin/Ki67 ratio when compared to the OED
groups and OSCC. The Mcm2/Ki67 ratio showed that Mcm2
expression was higher than Ki67 with a ratio of 1.75 (Table 1).
Mcm2, Ki67 and geminin protein were located mainly in the
suprabasal compartment. In most of the NOM samples there was a
characteristic absence of protein expression in the basal layer,
specially for Ki67 and geminin (Figure 1A–C).
Expression of cell-cycle proteins in oral epithelial
dysplasias
In all OED samples there was a higher expression of Mcm2 when
compared to Ki67 and geminin (Table 1; Figure 1D–F). Mcm2
Table 1 Mean and s.d. of Mcm2, Ki67 and geminin LI and median with percentiles in the Mcm2/Ki67 and geminin/Ki67 ratios in NOM, all OEDs and
OSCC
Labelling index mean (s.d.) Median (25–75%)
Mcm2 Ki67 Geminin Stat. GLM Mcm2/Ki67 ratio Geminin/Ki67 ratio
NOM (n¼15) 39.94 (8.1) 22.94 (5.2) 9.95 (2.1) Po0.001 1.75 (1.42–2.11) 0.43 (0.37–0.56)
OED (n¼81) 73.62 (12.1) 44.55 (11.1) 24.40 (7.2) Po0.001 1.75 (1.42–1.97)
a 0.54 (0.47–0.62)
OSCC (n¼38) 81.16 (4.9) 59.03 (9.6) 34.08 (6.3) Po0.001 1.36 (1.23–1.55) 0.58 (0.51–0.62)
ANOVA test Po0.001 Po0.001 Po0.001 PE¼0.00 PE¼0.01
Abbreviations: All OED¼all oral epithelial dysplasias (OED that progressed and did not progress to OSCC); GLM¼general linear model; NOM¼normal oral mucosa;
OSCC¼oral squamous-cell carcinomas from progressing OED; PE¼Kruskal-Wallis test; ANOVA¼analysis of variance.
aNote: The median Mcm2/Ki67 OED has a lower 75
percentile than NOM, therefore it has proportionally fewer high values, meaning it is actually lower hence the Kruskal–Wallis test.
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Figure 1 Immunoexpression pattern of proteins Mcm2 (A), Ki67 (B) and geminin (C) in NOM. Immunoexpression pattern of proteins Mcm2 (D), Ki67
(E) and geminin (F) in OED that progressed to OSCC. Original magnification  400.
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sexpression extended from the basal and suprabasal compartments
to the mid-prickle cell region (Figure 1D) and in some cases to the
surface layers.
Expression of Mcm2 was higher (P¼0.04) in the OED that
progressed to OSCC than in those that did not progress (Table 2).
In contrast, there was no significant difference in the geminin and
Ki67 LIs between the two OED groups (Table 2). The localisation of
Ki67 and geminin was expressed in the same areas as Mcm2, but in
a significantly (GLM Po0.001) lower proportion of cells (Table 2;
Figure 1E and F).
The Mcm2/Ki67 and geminin/Ki67 ratios (Table 2) were higher
in the OED with malignant progression compared to the OED with
no history of malignant transformation (P¼0.04 and 0.02
respectively).
There was no correlation between the grade of dysplasia and the
LI of the different proteins.
Expression of cell-cycle proteins in oral squamous-cell
carcinoma
Expression of Mcm2, Ki67 and geminin in the OSCC samples was
seen in a high number of epithelial cells with stronger staining
intensities at the invasive front (Figure 2A, C and D). When keratin
pearls were present expression of Mcm2, Ki67 and geminin was
seen around the periphery of the islands (Figure 2B).
The Mcm2/Ki67 ratio in OSCC was lower than in OED and
NOM, but the geminin/Ki67 ratio was increased (Table 1).
There was no correlation between the level of tumour
differentiation and the LI of the different proteins.
The LIs of Mcm2, Ki67 and geminin were progressively higher
from NOM through OED to OSCC (Table 1; ANOVAs, Po0.001).
In addition, there was a positive linear association between Mcm2
and Ki67 in all the analysed samples (Figure 3) as well as between
geminin and Ki67 (Figure 4).
DISCUSSION
Others have described the importance of pre-replication proteins,
especially Mcm2, as prognostic markers in dysplasias and
neoplasia at various sites in the human body (Williams et al,
1998, 2004; Stoeber et al, 1999; Meng et al, 2001; Wharton et al,
2001; Alison et al, 2002; Going et al, 2002; Eward et al, 2004;
Gonzalez et al, 2004; Dudderidge et al, 2005; Quaglia et al, 2006).
Table 2 Mean and s.d. of Mcm2, Ki67 and geminin LIs and median with percentiles in the Mcm2/Ki67 and geminin/Ki67 ratios in OEDs that progressed to
carcinoma and in OEDs with no malignant progression
Labelling index mean (s.d.) Median (25–75%)
Mcm2 Ki67 Geminin Stat. GLM Mcm2/Ki67 ratio Geminin/Ki67 ratio
OED no progr. (n¼40) 70.74 (12.84) 45.23 (11.17) 23.71 (7.0) Po0.001 1.63 (1.28–1.86) 0.51 (0.44–0.58)
OED progr. (n¼41) 76.28 (10.90) 43.90 (11.17) 25.06 (7.5) Po0.001 1.81 (1.52–2.03) 0.58 (0.48–0.68)
t-test P¼0.04 NS NS P’¼0.04 P’¼0.02
Abbreviations: GLM¼general linear model; OED no prog.¼oral epithelial dysplasias with no history of malignant progression; OED prog.¼oral epithelial dysplasias that
progressed to oral squamous-cell carcinoma; NS¼not significant; P’¼Mann–Whitney test.
Mcm2 Mcm2
Ki67 Geminin
Figure 2 Invasive front of OSCC, immunoexpression pattern of proteins Mcm2 (A), Mcm2 around a keratin pearl (B), Ki67 (C) and geminin
(D). Original magnification  400.
Mcm2 and geminin in oral epithelial dysplasias
A Torres-Rendon et al
1131
British Journal of Cancer (2009) 100(7), 1128–1134 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sIn the oral mucosa only a few studies have explored this (Kodani
et al, 2001, 2003; Scott et al, 2006). To the best of our knowledge,
this is the first study in which geminin or Mcm2/Ki67 and
geminin/Ki67 ratios have been evaluated in NOM or in oral
dysplasias and carcinomas. Overall geminin and Mcm2 showed a
clear association with proliferation (Ki67) and grade, the LI
increased from normal mucosa to OED to OSCC (Figures 3 and 4).
The results of this study suggest that in NOM, most cells are in
the G0 phase (not in cycle) with a lesser number in a licensed
G0–G1 transition (demonstrated by Mcm2 expression). Only about
20% of cells are actually in the cell cycle (demonstrated by Ki67
and geminin expression). This suggests that the epithelial basal
and suprabasal compartments in NOM have a low and controlled
proliferation rate but with a continuous proliferative capacity. Low
LIs in normal tissues have also been observed by other authors for
Mcm2 and Ki67 in oral mucosa (Kodani et al, 2001), larynx
(Chatrath et al, 2006) and prostate tissues (Meng et al, 2001), and
for geminin in breast tissue (Shetty et al, 2005).
The absence of Mcm2 expression in a significant proportion of
basal cells, and complete absence of Ki67 and geminin in this cell
layer of NOM observed in this study, suggests that these cells are in
a temporary G0 state. An in vitro study, using a fibroblast model
system coupled to a cell-free DNA replication assay, identified a
group of stem cells in intestinal epithelium that are unlicensed
(Mcm2 negative) and with no geminin expression. According to
the authors, these could be stem cells that may pass through a
prolonged cell cycle as a defensive mechanism against possible
genotoxic insult in rapidly proliferating tissues (Kingsbury et al,
2005). Similarly, a recent study (Takeda et al, 2006) has suggested
that stem cells are present in the basal layer of NOM, based on
expression of stem cell markers, cytokeratin 19 and p63. The low
expression of Mcm2 in the basal layer of the normal oral
epithelium was an unexpected finding but is in keeping with the
suggestion of a self-defence mechanism to maintain a controlled
cell proliferation of the oral mucosa.
In contrast to NOM, the levels of expression of Mcm2, geminin
and Ki67 were elevated in OED indicating a constant cell-cycle re-
entry with a high proportion of licensed and dividing cells. This
has also been observed in studies of Mcm2 and Ki67 in Barrett’s
oesophagus (Going et al, 2002) and in neoplastic oesophagus using
Mcm5 (Wharton et al, 2001).
The present study showed similar results to that of Kodani et al
(2001), although the LIs for Mcm2 and Ki67 were higher in our
study. The reason for this might be that Kodani et al quantified
cells throughout the whole thickness of the epithelium, from basal
to surface epithelial layers. Thus, the additional numbers of
differentiated and non-expressing epithelial cells included in the
upper third of the epithelium would have resulted in a lower
overall percentage of positive expression and a lower LI.
Quantification in the present study focused on the proliferative
epithelial compartments where Mcm2, Ki67 and geminin are
expressed more frequently. Other authors have evaluated Mcm2
and Ki67 in dysplastic lesions by dividing the epithelium into
compartments. Nevertheless, the results from Kodani et al were
similar to those reported here and showed a comparable increase
in expression from NOM to OSCC.
Although these results need to be confirmed by other similar
studies, Ki67 and geminin showed no significant difference
between the OED groups, however Mcm2 had a marginally but
significantly higher mean LI, in the OED that progressed to OSCC
than the OED with no history of malignant progression, this was
also observed previously (Kodani et al, 2001). These findings could
suggest that cells in OED with malignant progression have an
increased number of cells licensed to proliferate. Ibarra et al (2008)
observed that a full complement of MCM proteins is essential to
protect cells from the natural replicative stresses during S phase to
maintain genome integrity. Therefore, the high levels of Mcm2 in
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Figure 3 Scatter plot showing the positive association between the labelling indices for Mcm2 and Ki67 in NOM, OEDs and OSCC.
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Figure 4 Scatter plot displaying the positive association between Ki67
and geminin labelling indices in NOM, OEDs and OSCC.
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genomic damage before malignant transformation occurs.
The Mcm2/Ki67 ratio was higher in OED that progressed to
OSCC compared to OED with no malignant progression due to the
high levels of Mcm2 in the first group. Likewise, the geminin/Ki67
ratio was higher, indicating a shorter G1 phase and an increased
proliferation rate. Although the Mcm2/Ki67 and geminin/Ki67
ratios were significantly different between the OED with and
without malignant progression (Table 2), the differences in the
values are relatively small and this finding needs to be confirmed
in further similar studies.
The results suggest that cells in oral squamous-cell carcinoma
are in a high proliferation state as demonstrated by the high levels
of Mcm2, geminin and Ki67 (Table 1; Figure 2). Although the LI
for Mcm2 in the present study indicates that it is an effective
proliferation marker, Ki67 showed the biggest difference in values
from an LI of 44.55 in OED to 59.03 in OSCC (Table 1).
A significant rise in Ki67 expression has also been observed in
regenerative nodular lesions of cirrhotic liver that progressed to
hepatocellular carcinoma, but not for Mcm2 and geminin (Quaglia
et al, 2006).
The invasive front of OSCC was selected for protein evaluation,
because this is considered to be more relevant for the under-
standing of the cell-cycle kinetics of cells involved with invasion
into the adjacent tissues. This method may also be more
reproducible as it is easier to standardise evaluation of the inferior
limit (invasive front) of the lesion between different observers.
This is the first time that elevated geminin expression has been
reported in OSCC (Table 1). This finding is consistent with
previous immunohistochemical, immunoblotting and in situ
hybridisation studies where geminin is overexpressed in cancer
cell lines (Xouri et al, 2004) and unveiled as a proliferation marker
in different human cancers (Wohlschlegel et al, 2002).
Further studies of OSCC evaluating Mcm2, Ki67 and geminin
expression, along with their Mcm2/Ki67 and geminin/Ki67 LI
ratios, may provide further evidence of their prognostic potential,
especially if they can be correlated with mode of invasion, tumour
size and cumulative disease-free survival.
CONCLUSIONS
Overall the LI of all proteins increased progressively from
NOM to OED to OSCC. Geminin has been shown as a proliferative
marker in these oral tissues. Elevated levels of expression of
Mcm2, Ki67 and geminin in OED suggest a constant cell-cycle
re-entry. We also observed that Mcm2 as a proliferation marker
may be superior to Ki67 because it indicates licensed capacity.
In addition, Mcm2 was marginally but significantly more
elevated in OED that progressed to OSCC. The findings reported
here require confirmation from further studies; however, informa-
tion on Mcm2, Ki67 and geminin may be of prognostic value
in OEDs.
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